Company Overview and News
Oct 11, 2018 (LBO) – A large gathering of Institutional Investors based in London showed a keen interest in investing in Sri Lankan equities while attending an Invest Sri Lanka Forum held at the London Stock Exchange recently.
DIAL UBNC JKELF 55BC CBQS NTB HNB SAMP HPWR SPEN JKH LSE LNSTY SUN JKEHY
Sept 17, 2018 (LBO) – Outlining plans to support Sri Lanka in achieving the Sustainable Development Goals, Unilever Sri Lanka and United Nations Development Programme (UNDP) handed over a policy action paper for the promotion of public private partnerships for sustainable development to the secretary to President.
DIAL SPEN 55BC CBQS
Aug 06, 2018 (LBO) – The Committee on Public Enterprises (COPE), has summoned Ceylon Electricity Board (CEB), Ministry of Power and Renewable Energy and Public Utilities Commission of Sri Lanka (PUCSL) to investigate the purchasing of electricity from private power plants and requested to table the reports with relevant information by tomorrow (07th).
Jul 16, 2018 (LBO) – The Deputy General Manager, Energy Purchases of Ceylon Electricity Board (CEB) says that the Government should not pay the 100 MW ACE Embilipitiya as it is an illegal power plant.
July 13, 2018 (LBO) – Fitch Ratings has removed the Rating Watch Negative on Distilleries Company’s National Long-Term Rating, and has affirmed the rating at ‘AAA(lka)’.
DIAL SPEN SLTL
Hatton National Bank as the Lead Arranger of the Syndicated Loan together with People’s Bank, DFCC and Bank of Ceylon signed off Loan Agreements to finance the setting up of Western Power Company’s waste to energy plant, the first of its kind in Sri Lanka. A subsidiary of Aitken Spence PLC, Western Power Company has scheduled the commission of the 10 Mega Watt facility by 2020, in Kerawalapitiya, Muthurajawela, that will consume all of Colombo Municipality’s solid garbage.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to CSE:SPEN / AITKEN SPENCE PLC on message board site Silicon Investor.